Recommended Topic Related To:

AdreView

"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

Multiple myeloma is a form of blood cancer that p"...

AdreView

AdreView Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

AdreView (iobenguane I 123) Injection is a diagnostic radiopharmaceutical used to detect certain kinds of cancer of the adrenal glands. Common side effects include dizziness, mild skin rash or itching, bleeding around your IV needle, or warmth, tingling, or cold feeling where the medicine was injected.

For adults ( ≥ 16 years of age), the recommended dose of AdreView is 10 mCi (370 MBq). For pediatric patients < 16 years of age weighing ≥ 70 kg, the recommended dose of AdreView is 10 mCi (370 MBq). AdreView may interact with atomoxetine, labetalol, maprotiline, reserpine, decongestant cold medicines, diet pills, other stimulants, antidepressants, or street drugs, especially cocaine. Tell your doctor all medications and supplements you use. It is unknown if AdreView will harm a fetus. Tell your doctor if you are pregnant before you are treated with this drug. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Do not breastfeed within 6 days after receiving AdreView. If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby.

Our AdreView (iobenguane I 123) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

AdreView in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

  • dizziness;
  • mild skin rash or itching;
  • bleeding around your IV needle; or
  • warmth, tingling, or cold feeling where the medicine was injected.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for AdreView (Iobenguane I 123 Injection for Intravenous Use) »

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

AdreView FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Clinical Study Experience

Serious adverse reactions were not observed in the AdreView (iobenguane i 123 injection for intravenous use) clinical study. The data described below reflect AdreView (iobenguane i 123 injection for intravenous use) exposure to 251 patients with known or suspected pheochromocytoma or neuroblastoma. The average ages were 49 years (range 17 - 88 years) for adults and, for pediatric patients, 4 years (range 1 month - 16 years). Slightly less than half the patients were male. All patients were monitored for adverse reactions over a 24 hour period following AdreView (iobenguane i 123 injection for intravenous use) administration.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences ( ≤ 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.

Postmarketing Experience

Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions have uncommonly been reported during the postmarketing use of AdreView [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for AdreView (Iobenguane I 123 Injection for Intravenous Use) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.